Pharmac have received an application for belantamb mafodotin. The application has been assigned to Pharmac’s Cancer Treatments Advisory Committee (CTAC) meeting to provide advice on Thursday 20 November 2025.
Myeloma New Zealand has written a letter in support of the application. A big thank you to the two patients on belantamb who helped us with the submission.
You can read the submission and others on our submissions page.